Filing Details

Accession Number:
0001209191-14-017880
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-03-06 16:33:00
Reporting Period:
2014-03-04
Filing Date:
2014-03-06
Accepted Time:
2014-03-06 16:33:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
949699 Pharmacyclics Inc PCYC Pharmaceutical Preparations (2834) 943148201
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1555209 S Paula Boultbee Sjovall C/O Pharmacyclics, Inc.
995 East Arques Avenue
Sunnyvale CA 94085
Evp, Sales And Marketing No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-03-04 13,747 $25.94 15,486 No 4 M Direct
Common Stock Disposition 2014-03-04 13,747 $137.07 1,739 No 4 S Direct
Common Stock Acquisiton 2014-03-05 6,253 $25.94 7,992 No 4 M Direct
Common Stock Disposition 2014-03-05 6,253 $140.75 1,739 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2014-03-04 13,747 $0.00 13,747 $25.94
Common Stock Stock Option (Right to Buy) Disposition 2014-03-05 6,253 $0.00 6,253 $25.94
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
186,253 2012-04-17 2022-04-17 No 4 M Direct
180,000 2012-04-17 2022-04-17 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 406 Indirect By Spouse
Footnotes
  1. The option shares vest 25% on each of April 11, 2013, April 11, 2014, April 11, 2015 and April 11, 2016, subject to satisfaction of certain performance criteria with respect to each vesting period. Such performance criteria is to be determined and approved by the Compensation Committee.